Adicet Bio to Present at Upcoming Investor Conferences
May 18 2022 - 4:00PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing first-in-class allogeneic gamma
delta chimeric antigen receptor (CAR) T cell therapies for cancer,
today announced that company management will participate in two
upcoming investor conferences in May and June.
Details of the events are as follows:
H.C. Wainwright Global Investment Conference, May 23-26,
2022
- An on-demand presentation will be available beginning Tuesday,
May 24th, 2022, at 7:00 A.M. ET.
Jefferies Healthcare Conference, June 8-10, 2022
- Chen Schor, President & CEO, will present on Friday, June
10, 2022 at 8:30 A.M. ET.
The live audio webcast of the presentations can be accessed on
the Investors section of Adicet Bio’s website at
https://investor.adicetbio.com. An archived replay will be
available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and
developing allogeneic gamma delta T cell therapies for cancer.
Adicet is advancing a pipeline of “off-the-shelf” gamma delta T
cells, engineered with CAR and T cell receptor-like targeting
moieties to enhance selective tumor targeting, facilitate innate
and adaptive anti-tumor immune response, and improve persistence
for durable activity in patients. For more information, please
visit our website at http://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220518005854/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jul 2024 to Aug 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Aug 2023 to Aug 2024